Perflubutane - Daiichi Sankyo/GE Healthcare

Drug Profile

Perflubutane - Daiichi Sankyo/GE Healthcare

Alternative Names: DD-723; DD-723-B; NC-100100; NUS; Sonazoid

Latest Information Update: 21 Nov 2017

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator GE Healthcare
  • Developer Daiichi Sankyo Company; GE Healthcare; Yonsei University Health System
  • Class Contrast media; Fluorocarbons; Small molecules
  • Mechanism of Action Ultrasonography enhancers
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Marketed Breast cancer; Liver cancer
  • Phase III Liver disorders
  • Discontinued Prostate cancer; Vascular disorders

Most Recent Events

  • 10 Aug 2012 Registered for Breast cancer in Japan (IV)
  • 31 Jan 2012 Preregistration for Breast cancer diagnosis in Japan (IV)
  • 29 Jan 2010 Phase-II clinical trials in Breast cancer diagnosis in Japan (IV)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top